BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7857707)

  • 1. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease.
    Berruti A; Tampellini M; Torta M; Buniva T; Gorzegno G; Dogliotti L
    Eur J Cancer; 1994; 30A(14):2082-4. PubMed ID: 7857707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.
    Tampellini M; Berruti A; Gerbino A; Buniva T; Torta M; Gorzegno G; Faggiuolo R; Cannone R; Farris A; Destefanis M; Moro G; Deltetto F; Dogliotti L
    Br J Cancer; 1997; 75(5):698-702. PubMed ID: 9043027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis.
    Cañizares F; Sola J; Pérez M; Tovar I; De Las Heras M; Salinas J; Peñafiel R; Martínez P
    Tumour Biol; 2001; 22(5):273-81. PubMed ID: 11553856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.
    Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D
    Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
    Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
    Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.
    Viot J; Bachour M; Meurisse A; Pivot X; Fiteni F
    Breast; 2017 Aug; 34():53-57. PubMed ID: 28505557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer.
    Li H; Chen K; Su F; Song E; Gong C
    J Surg Res; 2014 Jun; 189(1):48-56. PubMed ID: 24680287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
    Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma TuM2-PK correlates with tumor size, CRP and CA 15-3 in metastatic breast carcinomas; short versus long term follow up study of the Egyptian breast cancer patients.
    El-Abd E; El-Sheikh M; Zaky S; Fayed W; El-Zoghby S
    Cancer Biomark; 2017 Aug; 20(2):123-133. PubMed ID: 28869444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of CA 15.3 kinetics for metastatic breast cancer.
    De La Lande B; Hacene K; Floiras JL; Alatrakchi N; Pichon MF
    Int J Biol Markers; 2002; 17(4):231-8. PubMed ID: 12521126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated CA125 in breast cancer--A sign of advanced disease.
    Norum LF; Erikstein B; Nustad K
    Tumour Biol; 2001; 22(4):223-8. PubMed ID: 11399947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
    Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
    Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer.
    Kumpulainen EJ; Keskikuru RJ; Johansson RT
    Breast Cancer Res Treat; 2002 Nov; 76(2):95-102. PubMed ID: 12452445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse.
    Tampellini M; Berruti A; Gorzegno G; Bitossi R; Bottini A; Durando A; De Matteis A; Farris A; Donadio M; De Fabiani E; Manzin E; Arese P; Sarobba MG; Castiglione F; Moro G; Bonazzi G; Nuzzo F; Massobrio M; Dogliotti L
    Tumour Biol; 2001; 22(6):367-73. PubMed ID: 11786730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of CA 15-3 serum levels in breast cancer patients.
    Skrzydlewski Z; Niklinski J; Kiluk S; Kiluk M; Musiatowicz B; Zaremba E; Skrzydlewska E; Klepacki A
    Minerva Chir; 1997 Mar; 52(3):251-4. PubMed ID: 9099053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.